SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Katsanos Konstantinos) "

Sökning: WFRF:(Katsanos Konstantinos)

  • Resultat 1-10 av 14
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Mauri, Davide, et al. (författare)
  • Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy : Time to Rethink Our Approach
  • 2022
  • Ingår i: Oncology Research and Treatment. - : S. Karger. - 2296-5270 .- 2296-5262. ; 45:4, s. 216-220
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge.Summary: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the implementation of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) and identify druggable mutations or recovery of RAS-wildness. In this opinion paper, we summarize with critical thinking the clinical approach to be followed after the failure of first-line treatment in Ras wild-type CRC tumors with the use of NGS. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS. The use of NGS platforms for serial analysis of ctDNA is an important step to better understand the molecular landscape of metastatic CRC and guide clinical decisions.Key Messages: NGS should be considered a mainstay in clinical practice for the management of CRC patients and health authorities should consider reimbursing its use in the appropriate clinical settings.
  •  
2.
  • Phillips, Frank, et al. (författare)
  • Orofacial Granulomatosis associated with Crohn's Disease : a multi-centre case series
  • 2022
  • Ingår i: Journal of Crohn's & Colitis. - : Elsevier. - 1873-9946 .- 1876-4479. ; 16:3, s. 430-435
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Orofacial granulomatosis (OFG) is a rare syndrome that may be associated with Crohn's disease (CD). We aimed to characterise this relationship and the management options in the biologic era.METHODS: This multicentre case series was supported by the European Crohn's and Colitis Organisation (ECCO), and performed as part of the Collaborative Network of Exceptionally Rare case reports (CONFER) project. Clinical data were recorded in a standardised collection form.RESULTS: This report includes 28 patients with OFG associated with CD: 14 males (mean age of 32 years, ±12.4 SD) and 14 females (40.3 years, ±21.0 SD). Non-oral upper gastrointestinal tract involvement was seen in 6 cases and perianal disease in 11. The diagnosis of OFG was made prior to CD diagnosis in 2 patients, concurrently in 8 and after CD diagnosis in 18. The distribution of OFG involved the lips in 16 cases and buccal mucosa in 18. Pain was present in 25 cases, with impaired swallowing or speaking in 6. Remission was achieved in 23 patients, notably with the use of anti-TNFs in 9 patients, vedolizumab in 1, ustekinumab in 1 and thalidomide in 2. A further 5 cases were resistant to therapies including anti-TNFs.CONCLUSION: OFG associated with CD may occur before, concurrently or after the diagnosis of CD. Perianal and UGI disease are common associations and there is a significant symptom burden in many. Remission can be obtained with a variety of immunosuppressive treatments, including several CD approved biologicals.
  •  
3.
  • Adamina, Michel, et al. (författare)
  • ECCO Guidelines on Therapeutics in Crohns Disease: Surgical Treatment
  • 2020
  • Ingår i: Journal of Crohn's & Colitis. - : OXFORD UNIV PRESS. - 1873-9946 .- 1876-4479. ; 14:2, s. 155-168
  • Tidskriftsartikel (refereegranskat)abstract
    • This article is the second in a series of two publications relating to the European Crohns and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohns disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohns disease and an update of previous guidelines.
  •  
4.
  • Adamina, Michel, et al. (författare)
  • ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology Collaboration Between S-ECCO, EduCom, H-ECCO
  • 2021
  • Ingår i: Journal of Crohn's & Colitis. - : OXFORD UNIV PRESS. - 1873-9946 .- 1876-4479. ; 15:7, s. 1089-1105
  • Forskningsöversikt (refereegranskat)abstract
    • Background and Aims: Diagnosis and management of inflammatory bowel diseases [IBD] requires a lifelong multidisciplinary approach.The quality of medical reporting is crucial in this context.The present topical review addresses the need for optimised reporting in endoscopy, surgery, and histopathology. Methods: A consensus expert panel consisting of gastroenterologists, surgeons, and pathologists, convened by the European Crohns and Colitis Organisation, performed a systematic literature review. The following topics were covered: in endoscopy: [i] general IBD endoscopy; [ii] disease activity and surveillance; [iii] endoscopy treatment in IBD; in surgery: [iv] medical history with surgical relevance, surgical indication, and strategy; [v] operative approach; [vi] intraoperative disease description; [vii] operative steps; in pathology: [viii] macroscopic assessment and interpretation of resection specimens; [ix] IBD histology, including biopsies, surgical resections, and neoplasia; [x] IBD histology conclusion and report. Statements were developed using a Delphi methodology incorporating two consecutive rounds. Current practice positions were set when >= 80% of participants agreed on a recommendation. Results: Thirty practice positions established a standard terminology for optimal reporting in endoscopy, surgery, and histopathology. Assessment of disease activity, surveillance recommendations, advice to surgeons for operative indication and strategies, including margins and extent of resection, and diagnostic criteria of IBD, as well as guidance for the interpretation of dysplasia and cancer, were handled. A standardised report including a core set of items to include in each specialty report, was defined. Conclusions: Interdisciplinary high-quality care requires thorough and standardised reporting across specialties.This topical review offers an actionable framework and practice recommendations to optimise reporting in endoscopy, surgery, and histopathology.
  •  
5.
  • Alexandropoulos, G. C., et al. (författare)
  • RIS-enabled smart wireless environments: deployment scenarios, network architecture, bandwidth and area of influence
  • 2023
  • Ingår i: Eurasip Journal on Wireless Communications and Networking. - 1687-1499 .- 1687-1472. ; 2023:1
  • Forskningsöversikt (refereegranskat)abstract
    • Reconfigurable intelligent surfaces (RISs) constitute the key enabler for programmable electromagnetic propagation environments and are lately being considered as a candidate physical-layer technology for the demanding connectivity, reliability, localisation, and sustainability requirements of next-generation wireless networks. In this paper, we first present the deployment scenarios for RIS-enabled smart wireless environments that have been recently designed within the ongoing European Union Horizon 2020 RISE-6G project, as well as a network architecture integrating RISs with existing standardised interfaces. We identify various RIS deployment strategies and sketch the core architectural requirements in terms of RIS control and signalling, depending on the RIS hardware architectures and respective capabilities. Furthermore, we introduce and discuss, with the aid of simulations and reflect array measurements, two novel metrics that emerge in the context of RIS-empowered wireless systems: the RIS bandwidth of influence and the RIS area of influence. Their extensive investigation corroborates the need for careful deployment and planning of the RIS technology in future wireless networks.
  •  
6.
  • Alexandropoulos, G. C., et al. (författare)
  • Smart Wireless Environments Enabled by RISs: Deployment Scenarios and Two Key Challenges
  • 2022
  • Ingår i: 2022 Joint European Conference on Networks and Communications and 6G Summit, EuCNC/6G Summit 2022. ; , s. 1-6
  • Konferensbidrag (refereegranskat)abstract
    • Reconfigurable Intelligent Surfaces (RISs) constitute the enabler for programmable propagation of electromagnetic signals, and are lately being considered as a candidate physicallayer technology for the demanding connectivity, reliability, localization, and sustainability requirements of next generation wireless communications networks. In this paper, we present various deployment scenarios for RIS-enabled smart wireless environments that have been recently designed by the ongoing EU H2020 RISE-6G project. The scenarios are taxonomized according to performance objectives, in particular, connectivity and reliability, localization and sensing, as well as sustainability and secrecy. We identify various deployment strategies and sketch the core architectural requirements in terms of RIS control and signaling, depending on the RIS hardware architectures and their respective capabilities. Furthermore, we introduce and discuss, via preliminary simulation results and reflectarray measurements, two key novel challenges with RIS-enabled smart wireless environments, namely, the area of influence and the bandwidth of influence of RISs, which corroborate the need for careful deployment and planning of this new technology.
  •  
7.
  • Burisch, Johan, et al. (författare)
  • Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort : an Epi-IBD study
  • 2019
  • Ingår i: Journal of Gastroenterology and Hepatology. - : John Wiley & Sons. - 0815-9319 .- 1440-1746. ; 34:6, s. 996-1003
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: A definitive diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) is not always possible and a proportion of patients will be diagnosed as inflammatory bowel disease unclassified (IBDU). The aim of the study was to investigate the prognosis of patients initially diagnosed with IBDU and the disease course during the following five years.METHODS: The Epi-IBD study is a prospective population-based cohort of 1,289 IBD patients diagnosed in centres across Europe. Clinical data were captured prospectively throughout the follow-up period.RESULTS: Overall, 476 (37%) patients were initially diagnosed with CD, 701 (54%) with UC, and 112 (9%) with IBDU. During follow-up, 28 (25%) IBDU patients were changed diagnoses to either UC (n=20, 71%) or CD (n=8, 29%) after a median of six months (IQR: 4-12), while 84 (7% of the total cohort) remained IBDU. A total of 17 (15%) IBDU patients were hospitalized for their IBD during follow-up, while 8 (7%) patients underwent surgery. Most surgeries (n=6, 75%) were performed on patients whose diagnosis was later changed to UC; three of these colectomies led to a definitive diagnosis of UC. Most patients (n=107, 96%) received 5-aminosalicylic acid, while 11 (10%) patients received biologicals, of whom five remained classified as IBDU.CONCLUSIONS: In a population-based inception cohort, 7% of IBD patients were not given a definitive diagnosis of IBD after five years of follow-up. One in four patients with IBDU eventually were classified as CD or UC. Overall, the disease course and medication burden in IBDU patients were mild.
  •  
8.
  • Burisch, Johan, et al. (författare)
  • Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study
  • 2019
  • Ingår i: Journal of Crohn's & Colitis. - : Oxford University Press. - 1873-9946 .- 1876-4479. ; 13:2, s. 198-208
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort.Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8].Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.
  •  
9.
  •  
10.
  • Kabir, Misha, et al. (författare)
  • DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making
  • 2023
  • Ingår i: Journal of Crohn's & Colitis. - : OXFORD UNIV PRESS. - 1873-9946 .- 1876-4479. ; 17:10, s. 1652-1671
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and Aims Inflammatory bowel disease colitis-associated dysplasia is managed with either enhanced surveillance and endoscopic resection or prophylactic surgery. The rate of progression to cancer after a dysplasia diagnosis remains uncertain in many cases and patients have high thresholds for accepting proctocolectomy. Individualised discussion of management options is encouraged to take place between patients and their multidisciplinary teams for best outcomes. We aimed to develop a toolkit to support a structured, multidisciplinary and shared decision-making approach to discussions about dysplasia management options between clinicians and their patients. Methods Evidence from systematic literature reviews, mixed-methods studies conducted with key stakeholders, and decision-making expert recommendations were consolidated to draft consensus statements by the DECIDE steering group. These were then subjected to an international, multidisciplinary modified electronic Delphi process until an a priori threshold of 80% agreement was achieved to establish consensus for each statement. Results In all, 31 members [15 gastroenterologists, 14 colorectal surgeons and two nurse specialists] from nine countries formed the Delphi panel. We present the 18 consensus statements generated after two iterative rounds of anonymous voting. Conclusions By consolidating evidence for best practice using literature review and key stakeholder and decision-making expert consultation, we have developed international consensus recommendations to support health care professionals counselling patients on the management of high cancer risk colitis-associated dysplasia. The final toolkit includes clinician and patient decision aids to facilitate shared decision-making.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 14
Typ av publikation
tidskriftsartikel (11)
forskningsöversikt (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (14)
Författare/redaktör
Katsanos, Konstantin ... (7)
Ellul, Pierre (6)
Magro, Fernando (6)
Burisch, Johan (5)
Myrelid, Pär (4)
Spinelli, Antonino (4)
visa fler...
Adamina, Michel (3)
Warusavitarne, Janin ... (3)
Fiorino, Gionata (3)
Gisbert, Javier P. (3)
Gomollon, Fernando (3)
Juillerat, Pascal (3)
Pellino, Gianluca (3)
Torres, Joana (3)
Vavricka, Stephan (3)
Verstockt, Bram (3)
Halfvarson, Jonas, 1 ... (3)
Wymeersch, Henk, 197 ... (2)
Alexandropoulos, G. ... (2)
Bonovas, Stefanos (2)
Raine, Tim (2)
Armuzzi, Alessandro (2)
Bachmann, Oliver (2)
Bager, Palle (2)
Biancone, Livia (2)
Bokemeyer, Bernd (2)
Bossuyt, Peter (2)
Collins, Paul (2)
Doherty, Glen (2)
El-Hussuna, Alaa (2)
Frei-Lanter, Corneli ... (2)
Furfaro, Federica (2)
Gingert, Christian (2)
Gionchetti, Paolo (2)
Gordon, Hannah (2)
Hlavaty, Tibor (2)
Kopylov, Uri (2)
Krustins, Eduards (2)
Kucharzik, Torsten (2)
Lytras, Theodore (2)
Maaser, Christian (2)
Marshall, John Kenne ... (2)
Rosa, Isadora (2)
Sabino, Joao (2)
Savarino, Edoardo (2)
Stassen, Laurents (2)
Uzzan, Mathieu (2)
Zmora, Oded (2)
Bergemalm, Daniel, 1 ... (2)
Eriksson, Carl, 1981 ... (2)
visa färre...
Lärosäte
Linköpings universitet (6)
Örebro universitet (5)
Chalmers tekniska högskola (2)
Karolinska Institutet (2)
Uppsala universitet (1)
Språk
Engelska (14)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (12)
Teknik (2)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy